4Tech Appoints Global VP of Regulatory Affairs

4Tech Inc., which is developing the world’s first transcatheter device, TriCinch, for repair of the Tricuspid heart valve, has appointed Paul Cornelison, as vice president of regulatory affairs, quality assurance and clinical affairs.

Most recently, Cornelison was vice president of regulatory affairs, quality assurance and clinical affairs at CardiAQ Valve Technologies Inc., a developer of transcatheter mitral valve replacement (recently acquired by Edwards Lifesciences). Previously Cornelison served as vice president of regulatory affairs and quality assurance at Cardiac Dimensions Inc., one of the earliest percutaneous mitral valve repair companies. Earlier in his career, he held regulatory and quality assurance positions at Arrow International (now part of Teleflex Medical), RCRI Inc., St. Jude Medical Inc., (Daig Division), Angeion Corporation, Telectronics Pacing Systems, Aequitron Medical and Lake Region Manufacturing.

Cornelison holds a master’s degree in engineering (management of technology) from the University of Pennsylvania, and a B.A. in management and spanish from St. Johns’ University in Minnesota.

“Paul offers a broad range of quality, regulatory and clinical experience from nearly 25 years in the medical device industry, and has been a pioneer in the field of transcatheter valve therapies,” said Carine Schorochoff, co-founder and CEO of 4Tech. “As we finalize our second-generation 4Tech TriCinch system and prepare to start definitive clinical trials, I cannot think of anyone more qualified to pave the way for the European approval of the first transcatheter tricuspid repair technology.”

4Tech Inc. is incorporated in Delaware and has operations in Galway, Ireland (4Tech Cardio Ltd). 4Tech has developed a proprietary transcatheter solution for the treatment of tricuspid regurgitation (TR). Because of its anchoring and tensioning mechanism, the 4Tech TriCinch System for Transcatheter Tricuspid Valve Repair allows a simple and reproducible percutaneous procedure, designed to reduce TR and restore patient quality of life, while also allowing substantial potential healthcare cost savings.